Erythropoietin
Erythropoietin (EPO) is a glycoprotein produced primarily by the kidney in response to tissue hypoxia, and is the principal factor regulating red blood cell production. It stimulates erythroid precursors in the bone marrow to proliferate and mature into morphologically identifiable red blood cells. This hormone acts by binding to specific high-affinity receptors on erythroid precursors. EPO can be made synthetically and has been used as a performance-enhancing drug. The danger in misusing this drug is that too many RBCs increases the viscosity of the blood, and further dehydration can promote the development of strokes, heart attacks, etc. Failure to produce adequate quantities of EPO leads to severe anemia, a situation most often encountered in patients with end stage renal disease. For example, chronic renal disease and renal failure may result in decreased renal EPO synthesis and, subsequently, anemia. Hypoxia or decreased oxygen supply stimulates EPO release, which in turn stimulates bone marrow erythropoiesis.
In contrast, elevated levels of RBC, hemoglobin, hematocrit, or oxygen suppress the release of EPO and erythropoiesis. An example is polycythemia vera. Polycythemia vera is a neoplastic clonal blood disorder with autonomous proliferation of red blood cells, which results in a negative feedback or suppression of EPO. Patients with polycythemia vera have extremely elevated hemoglobin or hematocrit, and decreased serum erythropoietin level. Patients with EPO-independent anemia or anemia due to other causes have elevated concentrations of EPO. Examples include iron deficiency, aplastic anemia, sickle cell anemia, thalassemia, megaloblastic anemia, and myelodysplastic syndromes. In addition to renal failure, other conditions such as chronic infections, chronic inflammation, and malignancies might lower EPO levels. Secondary polycythemias (high altitude, pulmonary fibrosis) also might lower EPO levels. Some tumors secrete EPO or EPO-like proteins and cause erythrocytosis. Examples include renal cell carcinoma, Wilm's tumor, hepatoma, cerebellar hemangioblastoma, adrenal tumors, and leiomyoma. Slight increases in EPO levels are seen in pregnancy.
- As an aid in diagnosis of chronic renal disease and renal failure
- As an aid in diagnosis of EPO nonresponsive bone marrow anemias such as aplastic anemia, iron deficiency anemia, sickle cell anemia, thalassemia, megaloblastic anemia
- As an aid in diagnosis of myeloproliferative disorders such as idiopathic myelofibrosis and polycythemia vera
- As an aid in diagnosis of hemolytic anemia
- Differential diagnosis of primary from secondary polycythemia
- In diagnosis of EPO-producing tumors
Increased in:
- Independent anemias such as aplastic anemia, iron deficiency anemia, hemolytic anemia, sickle cell anemia, thalassemia, megaloblastic anemia, and myelodysplastic syndromes
- EPO producing tumors such as renal cell carcinoma, Wilm's tumor, cerebellar hemangioblastoma, adrenal tumors, and leiomyoma
- In kidney transplant rejection
- Pregnancy
- Polycystic kidney disease
- Treatment with recombinant human EPO (e.g., Epogen)
Decreased in:
- Anemia of chronic disease
- Chronic renal disease and renal failure
- Inflammatory states
- Polycythemia vera
- AZT treatment (HIV therapy)
5-30 mU/mL (5-30 U/L)
Radioimmunoassay, enzyme linked immunoassay (ELISA), immunochemiluminometric assay.
Serum (SST) or Plasma.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: 28 days
- Blood Rev. 1989 Jun;3(2):130-5. [PMID: 2673445]
- Haematologica. 1998 Aug;83(8):724-32. [PMID: 9793257]
- JAMA. 2005;293:90. [PMID: 15632341]
- Hematol Oncol Clin North Am. 1989 Sep;3(3):369-400. [PMID: 2561121]
- N Engl J Med. 2005;352:1011. [PMID: 15758012]
- Mayo Clin Proc. 2006;81:1188. [PMID: 16970215]